Details of the Drug Combinations

General Information of This Drug (ID: DMM9F25)

• Drug Name: LDE225 (DMM9F25)
• Synonyms: Erismodegib

Indication

Basal cell carcinoma; ICD 11: 2C32; Status: Approved [1]; Medulloblastoma; ICD 11: 2A00.10; Status: Phase 2 [2]; Skin cancer; ICD 11: 2C30-2C37; Status: Phase 2 [3]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Docetaxel + LDE225	DCRSET1	Docetaxel	Advanced Breast Cancer	[4]
Vismodegib + LDE225	DCOSQSX	Vismodegib	Basal Cell Carcinoma	[5]
Imiquimod + LDE225	DCAO0E8	Imiquimod	Basal Cell Carcinoma	[6]
LDE225 + Bortezomib	DC8ASPV	Bortezomib	Multiple Myeloma	[7]

References

• [1] The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016 Jul;75(1):113-125.e5.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8199).
• [4] ClinicalTrials.gov (NCT02027376) Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients
• [5] ClinicalTrials.gov (NCT05463757) Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
• [6] ClinicalTrials.gov (NCT03534947) A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma
• [7] ClinicalTrials.gov (NCT02254551) Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma